Skip to main content
Pharmaron Beijing Co., Ltd. logo

Pharmaron Beijing Co., Ltd. — Investor Relations & Filings

Ticker · 300759 ISIN · CNE100003JW4 LEI · 300300JYXHGVS5SNGG54 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,320 across all filing types
Latest filing 2026-03-30 Environmental & Social …
Country CN China
Listing Shenzhen Stock Exchange 300759

About Pharmaron Beijing Co., Ltd.

https://www.pharmaron.cn

Pharmaron Beijing Co., Ltd. is a premier R&D service provider for the life sciences industry, offering a comprehensive, fully integrated platform for drug discovery, development, and manufacturing. The company supports global pharmaceutical and biotechnology partners through a wide range of services, including laboratory chemistry, biology, DMPK, pharmacology, and safety assessment. Its capabilities extend to clinical development services and commercial-scale manufacturing for small molecules, biologics, and cell and gene therapies. By leveraging advanced technology and a global network of facilities, the company facilitates the transition of drug candidates from initial concept to market approval, optimizing the efficiency and success of the drug development lifecycle.

Recent filings

Filing Released Lang Actions
2025年环境、社会及管治报告
Environmental & Social Information Classification · 95% confidence The document is titled "2025 环境、社会及管治报告" which translates to "2025 Environmental, Social and Governance (ESG) Report" for 康龙化成（北京）新药技术股份有限公司. It is described as the company's seventh annual ESG report covering the period from January 1, 2025 to December 31, 2025, aligning with the company's annual report period. The content includes detailed ESG governance, sustainability strategies, environmental performance, social responsibility, governance structure, and related appendices. It references compliance with ESG reporting codes from the Hong Kong Stock Exchange and Shenzhen Stock Exchange, and includes quantitative performance data, governance details, and external certifications. The document is comprehensive and focused on ESG factors rather than financial results or audit opinions. This matches the definition of Environmental & Social Information (Code: SR). The document length (15,000 characters) and detailed content confirm it is the full ESG report, not just an announcement or summary. Therefore, the correct classification is SR with high confidence.
2026-03-30 Chinese
内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled '内部控制审计报告' which translates to 'Internal Control Audit Report'. It is issued by a registered accounting firm (Ernst & Young) and addresses the effectiveness of internal controls over financial reporting as of December 31, 2025. The content includes auditor responsibilities, company responsibilities, and an audit opinion on internal control effectiveness. The document is relatively short (1027 characters) and focuses solely on the audit of internal controls, not a full annual report or financial statements. This matches the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles. It is not an Annual Report (10-K) or Interim Report (IR) because it does not contain comprehensive financial statements or full company activity. It is not a Regulatory Filing (RNS) because it is a formal audit report, not a certification or attestation letter. Therefore, the correct classification is AR with high confidence.
2026-03-30 Chinese
《公司章程》（2026年3月）
Governance Information Classification · 95% confidence The document is titled as the Articles of Association (章程) of 康龙化成（北京）新药技术股份有限公司, which is a detailed legal and organizational charter of the company. It includes chapters on general provisions, business scope, share issuance, shareholders and shareholder meetings, board of directors, management, financial accounting, audit, notices and announcements, mergers, amendments, and other governance-related topics. The content is focused on the company's internal rules, shareholder rights, board structure, and governance practices. There is no indication that this is an annual report, audit report, earnings release, or any other financial or regulatory filing. Instead, it is a governance document outlining the company's constitution and operational framework. Therefore, the appropriate classification is Governance Information (CGR). The document length (15,000 characters) and detailed content support this classification with high confidence.
2026-03-30 Chinese
董事会关于独立非执行董事独立性自查情况的专项意见
Governance Information Classification · 95% confidence The document is a statement from the board of directors regarding the independence self-assessment of independent non-executive directors. It references compliance with listing rules and regulations related to independent directors, and it provides a formal opinion on their independence. There is no financial data, no mention of financial results, no shareholder voting results, no capital changes, or other report types. The document is a governance-related statement about board members' independence and qualifications. Therefore, it fits best under Governance Information (CGR). The document length is short and it is not an announcement of a report publication, so it is not RPA or RNS.
2026-03-30 Chinese
2025年度独立非执行董事述职报告（李丽华）
Board/Management Information Classification · 95% confidence The document is titled as the "2025年度独立非执行董事述职报告" which translates to the "2025 Annual Independent Non-Executive Director's Work Report." It is a detailed report by an independent non-executive director about their duties, attendance, and activities during the year 2025. The content includes descriptions of board meetings, committee meetings, attendance records, oversight activities, and evaluations of company governance and compliance. It does not contain financial statements or earnings data, nor is it an announcement or proxy solicitation. It is a management-related report focusing on board and director activities and governance oversight. Therefore, it fits best under the category of Board/Management Information (MANG). The document length (7422 characters) and detailed content confirm it is a full report, not a brief announcement or certification.
2026-03-30 Chinese
关于2026年度套期保值产品交易额度预计的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by the company Kanglong Huacheng (Beijing) New Drug Technology Co., Ltd. regarding the expected transaction quota for hedging products for the year 2026. It details the purpose, types, amounts, risk analysis, risk control measures, accounting treatment, and approval procedures related to the hedging transactions. The document is a formal disclosure about planned financial derivative transactions to hedge currency and interest rate risks, including board meeting resolutions and shareholder approval requirements. It does not contain actual financial statements or results, nor is it a report or transcript. It is a regulatory announcement about capital/financing activities related to hedging and risk management. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is under 5,000 characters but contains substantive information about financing activities rather than just announcing a report publication, so it is not RPA or RNS. Confidence is high due to clear content focus on hedging transaction quota and risk management.
2026-03-30 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.